Study guide
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing
Oregon Multistate Pharmacy Jurisprudence Examination MPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Oregon Legal Framework
1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy
2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities
2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection
3 Chapter 3: Pharmacy Technicians, Interns & Preceptors
3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision
4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners
4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
5 Chapter 5: Prescriber Authority & Prescription Requirements
5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
7 Chapter 7: Counseling, Language Access & Confidentiality
7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy
8 Chapter 8: The Dispensing Process
8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse
9 Chapter 9: Nonprescription & Restricted Products
9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others
10 Chapter 10: Product Selection: Generic & Biologic Substitution
10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)
11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting
11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles
12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings
12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies
13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice
13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing
Key Takeaways Explain This Topic AI
An Oregon CDTM agreement must identify the participants and principal leads, the decisions the pharmacist may make, when to contact the practitioner, training and quality assurance.
Oregon CDTM agreements must be reviewed and updated, or discontinued, at least every two years under OAR 855-115-0315. There is no annual requirement.
Oregon pharmacists may order labs only under CDTM or a clinical pharmacy agreement, the formulary or protocols, a Health Screen Testing Permit, or to monitor drug therapy.
An Oregon pharmacy may perform CLIA-waived tests under ORS 689.661 if it holds an HHS certificate of waiver.
Oregon clinical pharmacy records are kept seven years, and immunization and prescribing training records six years (OAR 855-104-0055).
Last updated: October 2026
Why this matters
Area 2.2 covers the "conditions under which the pharmacist ... participates in the administration of drugs in the management of patients' therapy." In Oregon, pharmacists manage therapy through several distinct legal channels. Choosing the right one is often the point of an exam question:
Channel Source Needs an individual practitioner agreement?
Collaborative drug therapy management (CDTM) OAR 855-115-0315 Yes : a written agreement with a practitioner or organized group
Clinical pharmacy agreement ORS 689.005; OAR 855-006-0005 Yes: with a health care organization, physician or naturopathic physician
Medication therapy management (MTM) OAR 855-115-0320 No; it is a patient care service
Statewide protocol or formulary prescribing ORS 689.645; OAR 855-115-0330 to -0345 No , but the Board must adopt the protocol or formulary by rule (sections 6.2–6.6)
- Administering on a prescriber's order ORS 689.655 Needs a lawful order
- Collaborative drug therapy management (OAR 855-115-0315)
CDTM means a pharmacist participates in managing drug therapy under a written protocol . The protocol includes the dosage, frequency, duration and route of administration (OAR 855-006-0005). A CDTM arrangement may be between one practitioner and one pharmacist, or between an organized medical group (a hospital, clinic or group practice) and one or more pharmacists.
The written agreement must contain:
The participating pharmacists , identified by name or description.
The participating practitioners or group.
The principal pharmacist and practitioner responsible for developing, training, administering and assuring the quality of the arrangement.
The types of decisions the pharmacist may make . This includes the diseases, drugs or drug categories covered, the methods and decision criteria, documentation and communication procedures, and the circumstances requiring the pharmacist to contact the practitioner .
Training and competency requirements.
A quality-assurance mechanism with periodic review.
The practitioner's authorization of the pharmacist's participation.
A requirement that the arrangement be reviewed and updated, or discontinued, at least every two years .
The pharmacist must keep the agreement and records at the pharmacy and make them available to the health licensing boards on request. Prescriptions issued under CDTM must still identify the authorizing practitioner (OAR 855-041-1105). The Board's self-inspection form checks both the agreement elements and the two-year review. Therapeutic substitution outside the agreement is not permitted.
Warning
Some study aids say Oregon requires annual CPA review. The current rule says at least every two years . A pharmacist adjusting therapy under an agreement last reviewed 20 months ago is still within the rule.
Clinical pharmacy agreements and the practice of clinical pharmacy
ORS 689.005 defines the practice of clinical pharmacy as patient care that optimizes medication therapy, together with the patient's other practitioners. It includes post-diagnostic disease-state management and practice under a clinical pharmacy agreement . A clinical pharmacy agreement is between a pharmacist or pharmacy and a health care organization, a physician (ORS 677.010) or a naturopathic physician . Pharmacists may order and receive lab tests when managing therapy under such an agreement or under CDTM (OAR 855-115-0310(1)(a)).
Medication therapy management (OAR 855-115-0320)
MTM services aim to optimize therapeutic outcomes. They may include:
Health assessments and medication reviews.
Medication treatment plans, and selecting or modifying therapy (within the pharmacist's authority).
Monitoring safety and effectiveness.
Documenting care and communication with other providers.
MTM and comprehensive medication review are part of the statutory practice of pharmacy. First-year interns may observe MTM but not conduct it (OAR 855-120-0150).
Laboratory testing (OAR 855-115-0310; ORS 689.661)
A pharmacist may order and receive laboratory tests only when:
Managing therapy under a clinical pharmacy agreement or CDTM.
Providing a service under the formulary (OAR 855-115-0340) or a protocol (OAR 855-115-0345).
Operating under an OHA Health Screen Testing Permit (ORS chapter 438).
Monitoring a therapeutic response or adverse effect of drug therapy.
A pharmacy may itself perform tests whose analytes FDA has cleared under the CLIA regulations, if it holds a CLIA certificate of waiver from HHS (ORS 689.661). A laboratory operated in a drug outlet must have its license displayed (OAR 855-041-1190).
Consulting practice (OAR 855-115-0300)
A pharmacist serving an Oregon-licensed health care facility performs every duty the facility's licensure requires. For correctional facilities, long-term care, community-based care, hospital drug rooms and charitable pharmacies without other state requirements, the consultant provides:
Policies and procedures for security, storage and distribution.
Guidance on documenting administration or dispensing.
Education on request.
Consulting records are kept for three years .
Record retention for clinical services
Under OAR 855-104-0055, clinical pharmacy records are kept seven years . Training records for immunization and for protocol or formulary prescribing are kept six years , or uploaded to the Board's licensing system. Other records are kept three years.
Exam scenario
A hospital-affiliated clinic and four pharmacists sign a CDTM agreement for anticoagulation. It names the principal pharmacist and physician, lists warfarin dose-adjustment criteria, sets an INR level that triggers a call to the physician, requires annual competency checks, and was last reviewed 22 months ago. The pharmacists may adjust warfarin within its criteria. The agreement must be reviewed by the 24-month mark, and each adjustment is documented and kept for seven years. If a pharmacist switched a patient to apixaban, a drug not covered by the agreement, that would be prescribing outside the CDTM arrangement.